These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
405 related articles for article (PubMed ID: 12569558)
1. Identification of a naturally processed HLA-A*0201 HPV18 E7 T cell epitope by tumor cell mediated in vitro vaccination. Kather A; Ferrara A; Nonn M; Schinz M; Nieland J; Schneider A; Dürst M; Kaufmann AM Int J Cancer; 2003 Apr; 104(3):345-53. PubMed ID: 12569558 [TBL] [Abstract][Full Text] [Related]
2. Identification of an HLA-A24-restricted cytotoxic T lymphocyte epitope from human papillomavirus type-16 E6: the combined effects of bortezomib and interferon-gamma on the presentation of a cryptic epitope. Morishima S; Akatsuka Y; Nawa A; Kondo E; Kiyono T; Torikai H; Nakanishi T; Ito Y; Tsujimura K; Iwata K; Ito K; Kodera Y; Morishima Y; Kuzushima K; Takahashi T Int J Cancer; 2007 Feb; 120(3):594-604. PubMed ID: 17096336 [TBL] [Abstract][Full Text] [Related]
3. Dendritic cell-based tumor vaccine for cervical cancer I: in vitro stimulation with recombinant protein-pulsed dendritic cells induces specific T cells to HPV16 E7 or HPV18 E7. Nonn M; Schinz M; Zumbach K; Pawlita M; Schneider A; Dürst M; Kaufmann AM J Cancer Res Clin Oncol; 2003 Sep; 129(9):511-20. PubMed ID: 12905010 [TBL] [Abstract][Full Text] [Related]
4. Induction of human papillomavirus-specific CD4(+) and CD8(+) lymphocytes by E7-pulsed autologous dendritic cells in patients with human papillomavirus type 16- and 18-positive cervical cancer. Santin AD; Hermonat PL; Ravaggi A; Chiriva-Internati M; Zhan D; Pecorelli S; Parham GP; Cannon MJ J Virol; 1999 Jul; 73(7):5402-10. PubMed ID: 10364287 [TBL] [Abstract][Full Text] [Related]
5. Induction of tumor-specific cytotoxicity in tumor infiltrating lymphocytes by HPV16 and HPV18 E7-pulsed autologous dendritic cells in patients with cancer of the uterine cervix. Santin AD; Bellone S; Palmieri M; Bossini B; Roman JJ; Cannon MJ; Bignotti E; Canè S; Pecorelli S Gynecol Oncol; 2003 May; 89(2):271-80. PubMed ID: 12713991 [TBL] [Abstract][Full Text] [Related]
6. Definition of an HPV18/45 cross-reactive human T-cell epitope after DNA immunisation of HLA-A2/KB transgenic mice. McCarthy C; Youde SJ; Man S Int J Cancer; 2006 May; 118(10):2514-21. PubMed ID: 16353149 [TBL] [Abstract][Full Text] [Related]
7. Human CTL epitopes encoded by human papillomavirus type 16 E6 and E7 identified through in vivo and in vitro immunogenicity studies of HLA-A*0201-binding peptides. Ressing ME; Sette A; Brandt RM; Ruppert J; Wentworth PA; Hartman M; Oseroff C; Grey HM; Melief CJ; Kast WM J Immunol; 1995 Jun; 154(11):5934-43. PubMed ID: 7538538 [TBL] [Abstract][Full Text] [Related]
8. Limitations of HLA-transgenic mice in presentation of HLA-restricted cytotoxic T-cell epitopes from endogenously processed human papillomavirus type 16 E7 protein. Street MD; Doan T; Herd KA; Tindle RW Immunology; 2002 Aug; 106(4):526-36. PubMed ID: 12153516 [TBL] [Abstract][Full Text] [Related]
9. Expression of CD56 by human papillomavirus E7-specific CD8+ cytotoxic T lymphocytes correlates with increased intracellular perforin expression and enhanced cytotoxicity against HLA-A2-matched cervical tumor cells. Santin AD; Hermonat PL; Ravaggi A; Bellone S; Roman JJ; Jayaprabhu S; Pecorelli S; Parham GP; Cannon MJ Clin Cancer Res; 2001 Mar; 7(3 Suppl):804s-810s. PubMed ID: 11300476 [TBL] [Abstract][Full Text] [Related]
10. Use of fluorogenic histocompatibility leukocyte antigen-A*0201/HPV 16 E7 peptide complexes to isolate rare human cytotoxic T-lymphocyte-recognizing endogenous human papillomavirus antigens. Youde SJ; Dunbar PR; Evans EM; Fiander AN; Borysiewicz LK; Cerundolo V; Man S Cancer Res; 2000 Jan; 60(2):365-71. PubMed ID: 10667589 [TBL] [Abstract][Full Text] [Related]
11. Mapping of cytotoxic T lymphocytes epitopes in E7 antigen of human papillomavirus type 11. Xu Y; Zhu KJ; Chen XZ; Zhao KJ; Lu ZM; Cheng H Arch Dermatol Res; 2008 Jun; 300(5):235-42. PubMed ID: 18299861 [TBL] [Abstract][Full Text] [Related]
12. Identification of human MHC-I HPV18 E6/E7-specific CD8 + T cell epitopes and generation of an HPV18 E6/E7-expressing adenosquamous carcinoma in HLA-A2 transgenic mice. Peng S; Xing D; Ferrall L; Tsai YC; Hung CF; Wu TC J Biomed Sci; 2022 Oct; 29(1):80. PubMed ID: 36224625 [TBL] [Abstract][Full Text] [Related]
13. Cytotoxic T-lymphocyte responses to human papillomavirus type 16 E5 and E7 proteins and HLA-A*0201-restricted T-cell peptides in cervical cancer patients. Liu DW; Yang YC; Lin HF; Lin MF; Cheng YW; Chu CC; Tsao YP; Chen SL J Virol; 2007 Mar; 81(6):2869-79. PubMed ID: 17202211 [TBL] [Abstract][Full Text] [Related]
14. Synthetic peptides induce a cytotoxic response against human papillomavirus type-18. Castellanos MR; Hayes RL; Maiman MA Gynecol Oncol; 2001 Jul; 82(1):77-83. PubMed ID: 11426965 [TBL] [Abstract][Full Text] [Related]
15. [Preparation of HPV18 E7 peptide plus CpG vaccine and its immunologic effects in vitro]. Liao SJ; Zhang WN; Hu XJ; Jiang XF; Wang CY; Lu YP; Wang SX; Ma D Zhonghua Yi Xue Za Zhi; 2012 Jun; 92(23):1641-5. PubMed ID: 22944136 [TBL] [Abstract][Full Text] [Related]
16. HPV type 16 protein E7 HLA-A2 binding peptides are immunogenic but not processed and presented. Bauer M; Wagner H; Lipford GB Immunol Lett; 2000 Jan; 71(1):55-9. PubMed ID: 10709786 [TBL] [Abstract][Full Text] [Related]
17. Identification of HLA-A11-restricted CTL epitopes derived from HPV type 18 using DNA immunization. Chen HW; Leng CH; Liu HY; Cheng WF; Chang YW; Wu PY; Lien SP; Huang TY; Chiang SK; Lin MH; Tao MH; Chong P; Liu SJ Cancer Biol Ther; 2009 Nov; 8(21):2025-32. PubMed ID: 19738415 [TBL] [Abstract][Full Text] [Related]
18. A conserved E7-derived cytotoxic T lymphocyte epitope expressed on human papillomavirus 16-transformed HLA-A2+ epithelial cancers. Riemer AB; Keskin DB; Zhang G; Handley M; Anderson KS; Brusic V; Reinhold B; Reinherz EL J Biol Chem; 2010 Sep; 285(38):29608-22. PubMed ID: 20615877 [TBL] [Abstract][Full Text] [Related]
19. Human papillomavirus type 33 E7 peptides presented by HLA-DR*0402 to tumor-infiltrating T cells in cervical cancer. Höhn H; Pilch H; Günzel S; Neukirch C; Freitag K; Necker A; Maeurer MJ J Virol; 2000 Jul; 74(14):6632-6. PubMed ID: 10864677 [TBL] [Abstract][Full Text] [Related]
20. HLA-A2-restricted peripheral blood cytolytic T lymphocyte response to HPV type 16 proteins E6 and E7 from patients with neoplastic cervical lesions. Evans C; Bauer S; Grubert T; Brucker C; Baur S; Heeg K; Wagner H; Lipford GB Cancer Immunol Immunother; 1996 Mar; 42(3):151-60. PubMed ID: 8640843 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]